3 Bargain-Cheap Small Caps Worth a Second Look

The article examines three small-cap stocks with low P/E ratios that may offer value opportunities. Innoviva Inc. (INVA) is a biotech company with a diversified business model including royalties and strategic investments, with analysts projecting a 50% upside despite a projected 2026 earnings decline. Wendy's (WEN) faces consumer headwinds but is controlling costs and offers an 8%+ dividend yield, potentially attractive if economic conditions improve. Nabors Industries (NBR) is a momentum play in oil and gas drilling services that has benefited from rising oil prices, though upside from current levels is limited.

04/09/2026, 9:55 AM • Investing

Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute Analytica

The global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.

02/10/2026, 5:55 AM • GlobeNewswire

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Two biotech companies are highlighted as standout investments for 2026. Axsome Therapeutics has strong late-stage pipeline developments with FDA acceptance of supplemental applications for AXS-05 in Alzheimer's agitation treatment and support for AXS-12 for narcolepsy, with 19 of 20 analysts rating it a Buy and targeting 8% upside. Innoviva received FDA approval for Nuzolvence, a first-in-class oral antibiotic for gonorrhea with significant market potential, and has shown strong financial performance with analyst consensus price target nearly double current trading levels.

01/08/2026, 10:06 AM • Investing

Innoviva (INVA) Q2 Sales Jump 64%

Innoviva reported Q2 2025 earnings with $0.77 EPS and $100.3 million revenue, exceeding analyst expectations. Specialty therapeutics sales increased 54% year-over-year, driven by new product launches like GIAPREZA and ZEVTERA, while operating income declined due to increased R&D expenses.

08/06/2025, 11:17 PM • The Motley Fool